Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · IEX Real-Time Price · USD
4.490
+0.090 (2.05%)
At close: Jul 19, 2024, 4:00 PM
4.310
-0.180 (-4.01%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Synaptogenix Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Synaptogenix stock has a target of 14, which predicts an increase of 211.80% from the current stock price of 4.49.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $14 $14 $14 $14
Change +211.80% +211.80% +211.80% +211.80%

Analyst Ratings

According to 1 stock analyst, the rating for Synaptogenix is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Apr '24May '24Jun '24Jul '24
Strong Buy 0001
Buy 0000
Hold 1110
Sell 0000
Strong Sell 0000
Total 1111

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Maxim Group
Maxim Group
Strong Buy
Upgrades
$14
Strong Buy Upgrades $14 +211.80% Jul 11, 2024
Maxim Group
Maxim Group
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Dec 19, 2022
Maxim Group
Maxim Group
Strong Buy
Initiates
$350
Strong Buy Initiates $350 +7,695.10% Apr 12, 2022
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.67
from -29.50
EPS Next Year
-2.16
from -1.67
Year 2019202020212022202320242025
Revenue
-------
Revenue Growth
-------
EPS
-301.00-300.75-62.75-20.25-29.50-1.67-2.16
EPS Growth
-------
Forward PE
-------
No. Analysts -----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025
High n/a n/a
Avg n/a n/a
Low n/a n/a

Revenue Growth

Revenue Growth 20242025
High - -
Avg - -
Low - -

EPS Forecast

EPS 20242025
High -1.72 -2.23
Avg -1.67 -2.16
Low -1.61 -2.08

EPS Growth

EPS Growth 20242025
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.